BRIEF published on 12/05/2025 at 18:39, 11 months 1 day ago VALNEVA: Declaration of Shares and Voting Rights Euronext Paris Voting Rights Ordinary Shares Valneva 2025
PRESS RELEASE published on 12/05/2025 at 18:34, 11 months 1 day ago VALNEVA Declaration of shares and voting rights: November 30, 2025 VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form Euronext Paris Voting Rights Shares Valneva Double Voting Rights
PRESS RELEASE published on 12/05/2025 at 18:34, 11 months 1 day ago VALNEVA Déclaration d’actions et de droits de vote : 30 novembre 2025 VALNEVA déclare des actions et des droits de vote, dont un passage en droit de vote double et un exercice d'options de souscription d'actions. Informations sur le siège social et le marché réglementé Euronext Paris Déclaration Droits De Vote Actions Valneva
BRIEF published on 12/03/2025 at 11:03, 11 months 4 days ago Valneva SE : Développements prometteurs dans le domaine du vaccin contre la maladie de Lyme Valneva SE Vaccin Contre La Maladie De Lyme Prévisions Du Marché Pfizer VLA15
BRIEF published on 12/03/2025 at 11:03, 11 months 4 days ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 11 months 4 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 1 year ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
BRIEF published on 11/04/2025 at 07:05, 1 year ago L'essai de phase 1 de Valneva donne des résultats positifs pour le vaccin contre le Zika Valneva Immunogénicité Essai De Phase 1 Adjuvant Vaccin Contre Le Zika
PRESS RELEASE published on 11/04/2025 at 07:00, 1 year ago Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Valneva SE reports positive Phase 1 trial results for VLA1601, its second-generation Zika vaccine candidate, showing improved immune response. Safety and immunogenicity demonstrated in trial Phase 1 Trial Valneva SE Safety Immunogenicity Zika Vaccine
PRESS RELEASE published on 11/04/2025 at 07:00, 1 year ago Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika Valneva annonce des résultats positifs de phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika, montrant une réponse immunitaire améliorée Valneva Immunitaire Phase 1 Vaccin Zika
Published on 11/06/2026 at 22:15, 18 hours 34 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 1 day 3 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 1 day 4 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 1 day 4 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/07/2026 at 13:35, 3 hours 14 minutes ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 20 hours 34 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 20 hours 34 minutes ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:15, 21 hours 34 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 21 hours 49 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 19:06, 21 hours 43 minutes ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 21 hours 45 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 21 hours 48 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 21 hours 49 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
